ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Deucravacitinib"

  • Abstract Number: 0509 • ACR Convergence 2021

    Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

    Anjaneya Chimalakonda1, James Burke1, Lihong Cheng1, Ian Catlett1, Michael Tagen1, Qihong Zhao1, Aditya Patel1, Jun Shen1, Ihab Girgis1, Subhashis Banerjee1 and John Throup2, 1Bristol Myers Squibb, Princeton, NJ, 2Bristol Myers Squibb, Princeton

    Background/Purpose: Deucravacitinib is a novel, oral, allosteric agent that selectively inhibits intracellular signaling by binding to the tyrosine kinase 2 (TYK2) pseudokinase domain rather than…
  • Abstract Number: 1820 • ACR Convergence 2021

    Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Musculoskeletal Manifestations of Active PsA in a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

    Philip Mease1, Atul Deodhar2, Désirée van der Heijde3, Frank Behrens4, Alan Kivitz5, Tom Lehman6, Lan Wei6, Marleen Nys7, Subhashis Banerjee6 and Miroslawa Nowak6, 1Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, 2Oregon Health & Science University, Portland, OR, 3Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 4CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, 5Altoona Center for Clinical Research, Duncansville, PA, 6Bristol Myers Squibb, Princeton, NJ, 7Bristol Myers Squibb, Braine-l'Alleud, Belgium

    Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates IL-23, IL-12, and IFNα/β signaling. Deucravacitinib is a novel, oral selective inhibitor of TYK2…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies